[Form 4] STAAR SURGICAL CO Insider Trading Activity

Rhea-AI Filing Summary

STAAR Surgical’s interim co-CEO and president & COO Warren Foust reported equity compensation activity, mainly from restricted stock units (RSUs). On March 13, 2026, he received a grant of 45,117 RSUs, which will vest in three equal annual installments starting in 2027.

On March 12 and 14, 2026, previously granted RSUs vested and were converted into common stock through option code M transactions, totaling 37,500 shares acquired. Following these events, he directly held 63,588 shares of common stock and 45,117 RSUs subject to future vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Foust Warren

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Co-CEO and Pres. & COO

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		M		8,175(1)	A	$0	34,263	D
Common Stock	03/14/2026		M		19,550(3)	A	$0	53,813	D
Common Stock	03/14/2026		M		9,775(4)	A	$0	63,588(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(6)	03/12/2026		M			8,175	(1)	(1)	Common Stock	8,175	$0	8,175	D
Restricted Stock Units	$0(6)	03/13/2026		A		45,117		(2)	(2)	Common Stock	45,117	$0	45,117	D
Restricted Stock Units	$0(6)	03/14/2026		M			19,550	(3)	(3)	Common Stock	19,550	$0	39,101	D
Restricted Stock Units	$0(6)	03/14/2026		M			9,775	(4)	(4)	Common Stock	9,775	$0	19,551	D

Explanation of Responses:

1. Reflects restricted stock units (RSUs) granted to the Reporting Person on March 12, 2024. These RSUs vested as to 1/3 (8,175 shares) on March 12, 2025, 1/3 (8,175 shares) on March 12, 2026, and will vest as to 1/3 (8,175 shares) on March 12, 2027.

2. Reflects RSUs granted to the Reporting Person on March 13, 2026 in connection with annual equity award. These RSUs vest as to 1/3 (15,039 shares) on March 13, 2027, 1/3 (15,039 shares) on March 13, 2028, and 1/3 (15,039 shares) on March 13, 2029.

3. Reflects RSUs granted to the Reporting Person on March 14, 2025. These RSUs vested as to 1/3 (19,550 shares) on March 14, 2026, and will vest as to 1/3 (19,550 shares) on March 14, 2027, and 1/3 (19,551 shares) on March 14, 2028.

4. Reflects RSUs granted to the Reporting Person on March 14, 2025. These RSUs vested as to 1/3 (9,775 shares) on March 14, 2026, and will vest as to 1/3 (9,775 shares) on March 14, 2027, and 1/3 (9,776 shares) on March 14, 2028.

5. Includes previously granted RSUs, which are subject to future vesting.

6. Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.

	/s/ Warren Foust	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.